The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
The genetics of Alzheimer's disease
Open accessAbstract
Alzheimer's disease (AD) is a complex and heterogeneous neurodegenerative disorder, classified as either early onset (under 65 years of age), or late onset (over 65 years of age). Three main genes are involved in early onset AD: amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2). The apolipoprotein E (APOE) E4 allele has been found to be a main risk factor for late-onset Alzheimer's disease. Additionally, genome-wide association studies (GWASs) have identified several genes that might be potential risk factors for AD, including clusterin (CLU), complement receptor 1 (CR1), phosphatidylinositol binding clathrin assembly protein (PICALM), and sortilin-related receptor (SORL1). Recent studies have discovered additional novel genes that might be involved in late-onset AD, such as triggering receptor expressed on myeloid cells 2 (TREM2) and cluster of differentiation 33 (CD33). Identification of new AD-related genes is important for better understanding of the pathomechanisms leading to neurodegeneration. Since the differential diagnoses of neurodegenerative disorders are difficult, especially in the early stages, genetic testing is essential for diagnostic processes. Next-generation sequencing studies have been successfully used for detecting mutations, monitoring the epigenetic changes, and analyzing transcriptomes. These studies may be a promising approach toward understanding the complete genetic mechanisms of diverse genetic disorders such as AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 2×
“org).(152) Systematic meta-analyses were performed for each polymorphism with all genotype data described for them.”
Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., & Lannfelt, L. (1992) · Nature Genetics · doi:10.1038/ng0892-345 · Cited by 1,513
Chartier-Harlin, M.-C., Crawford, F., Houlden, H., Warren, A., Hughes, D., Fidani, L., Goate, A., Rossor, M., Roques, P., Hardy, J., et al. (1991) · Nature · doi:10.1038/353844a0 · Cited by 1,214
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
Bu, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2620 · Cited by 1,168
Cited by
Glycogen synthase kinase-3 signaling in Alzheimer's disease
Lauretti, E., Dincer, O., & Praticò, D. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118664 · Cited by 615
Therapeutic strategies for Alzheimer's disease in clinical trials
Godyń, J., Jończyk, J., Panek, D., & Malawska, B. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2015.07.006 · Cited by 452
Aging Microglia—Phenotypes, Functions and Implications for Age-Related Neurodegenerative Diseases
Spittau, B. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00194 · Cited by 253
PSEN1ΔE9, APPswe, and APOE4 Confer Disparate Phenotypes in Human iPSC-Derived Microglia
Konttinen, H., Cabral-da-Silva, M. E. C., Ohtonen, S., Wojciechowski, S., Shakirzyanova, A., Caligola, S., Giugno, R., Ishchenko, Y., Hernández, D., Fazaludeen, M. F., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.08.004 · Cited by 191
Bourgade, K., Le Page, A., Bocti, C., Witkowski, J. M., Dupuis, G., Frost, E. H., & Fülöp, T. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150652 · Cited by 161
Functional Roles of the Interaction of APP and Lipoprotein Receptors
Pohlkamp, T., Wasser, C. R., & Herz, J. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00054 · Cited by 92
Dietary Patterns and Alzheimer’s Disease: An Updated Review Linking Nutrition to Neuroscience
Ellouze, I., Sheffler, J., Nagpal, R., & Arjmandi, B. (2023) · Nutrients · doi:10.3390/nu15143204 · Cited by 104
“The first clinical symptoms of AD typically appear around 20 years after the initial structural changes in the brain [5,6].”
BackgroundIntegrative neurobiology of metabolic diseases, neuroinflammation, and neurodegeneration
van Dijk, G., van Heijningen, S., Reijne, A. C., Nyakas, C., van der Zee, E. A., & Eisel, U. L. M. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00173 · Cited by 75
Wang, C., Lu, J., Sha, X., Qiu, Y., Chen, H., & Yu, Z. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00935-z · Cited by 70
Ravanidis, S., Bougea, A., Karampatsi, D., Papagiannakis, N., Maniati, M., Stefanis, L., & Doxakis, E. (2021) · Movement Disorders · doi:10.1002/mds.28467 · Cited by 63
Asanomi, Y., Shigemizu, D., Miyashita, A., Mitsumori, R., Mori, T., Hara, N., Ito, K., Niida, S., Ikeuchi, T., & Ozaki, K. (2019) · Molecular Medicine · doi:10.1186/s10020-019-0090-5 · Cited by 47
Pandey, R. S., Graham, L., Uyar, A., Preuss, C., Howell, G. R., & Carter, G. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0351-3 · Cited by 37
Bhattacharjee, S., Zhao, Y., & Lukiw, W. J. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00116 · Cited by 34
Langella, S., Barksdale, N. G., Vasquez, D., Aguillon, D., Chen, Y., Su, Y., Acosta-Baena, N., Acosta-Uribe, J., Baena, A. Y., Garcia-Ospina, G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40775-z · Cited by 30
Predicting Alzheimer’s Disease Using Combined Imaging-Whole Genome SNP Data
Kong, D., Initiative, A. F. T. A. D. N., Giovanello, K. S., Wang, Y., Lin, W., Lee, E., Fan, Y., Murali Doraiswamy, P., & Zhu, H. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150164 · Cited by 26
Kitzlerová, E., Fišar, Z., Lelková, P., Jirák, R., Zvěřová, M., Hroudová, J., Manukyan, A., Martásek, P., & Raboch, J. (2018) · Medical Science Monitor · doi:10.12659/msm.907202 · Cited by 21
A functional variant of SHARPIN confers increased risk of late-onset Alzheimer’s disease
Asanomi, Y., Shigemizu, D., Akiyama, S., Miyashita, A., Mitsumori, R., Hara, N., Ikeuchi, T., Niida, S., & Ozaki, K. (2022) · Journal of Human Genetics · doi:10.1038/s10038-021-00987-x · Cited by 19
Bagaria, J., Moon, Y., Bagyinszky, E., Shim, K. H., An, S. S. A., Kim, S., & Han, S. H. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.899644 · Cited by 4
Self-citation
Metadata
- Authors
- Bagyinszky, E., Youn, Y. C., An, S., & Kim, S.
- Venue
- Clinical Interventions in Aging
- Publisher
- Informa UK Limited
- Published
- 2014-04
- Volume
- 9
- Pages
- 535
- ISSN
- 1176-9092 (ISSN-L)
- 1178-1998
- OpenAlex
- W1978065874
- Cited by
- 173
- References
- 29
- FWCI
- 10.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.